

S4 Table. Comparison of OS according to second-line treatments

	Median OS (mo)	95% CI
Afatinib → Osimertinib	54.3	48.5-NA
Afatinib → Pemetrexed-containing regimens	41.7	36.7-67.3
Afatinib → Pemetrexed-platinum doublet	50	37.6-NA
Afatinib → Pemetrexed monotherapy	36.5	27.0-NA

CI, confidence interval; NA, not available; OS, overall survival.